Your browser doesn't support javascript.
loading
Dissemination of Registered COVID-19 Clinical Trials (DIRECCT): a cross-sectional study.
Salholz-Hillel, Maia; Pugh-Jones, Molly; Hildebrand, Nicole; Schult, Tjada A; Schwietering, Johannes; Grabitz, Peter; Carlisle, Benjamin Gregory; Goldacre, Ben; Strech, Daniel; DeVito, Nicholas J.
Afiliação
  • Salholz-Hillel M; QUEST Center for Responsible Research, Berlin Institute of Health (BIH), Charite Universitätsmedizin Berlin, Berlin, Germany.
  • Pugh-Jones M; QUEST Center for Responsible Research, Berlin Institute of Health (BIH), Charite Universitätsmedizin Berlin, Berlin, Germany.
  • Hildebrand N; QUEST Center for Responsible Research, Berlin Institute of Health (BIH), Charite Universitätsmedizin Berlin, Berlin, Germany.
  • Schult TA; QUEST Center for Responsible Research, Berlin Institute of Health (BIH), Charite Universitätsmedizin Berlin, Berlin, Germany.
  • Schwietering J; QUEST Center for Responsible Research, Berlin Institute of Health (BIH), Charite Universitätsmedizin Berlin, Berlin, Germany.
  • Grabitz P; QUEST Center for Responsible Research, Berlin Institute of Health (BIH), Charite Universitätsmedizin Berlin, Berlin, Germany.
  • Carlisle BG; QUEST Center for Responsible Research, Berlin Institute of Health (BIH), Charite Universitätsmedizin Berlin, Berlin, Germany.
  • Goldacre B; Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
  • Strech D; QUEST Center for Responsible Research, Berlin Institute of Health (BIH), Charite Universitätsmedizin Berlin, Berlin, Germany.
  • DeVito NJ; Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK. nicholas.devito@phc.ox.ac.uk.
BMC Med ; 21(1): 475, 2023 11 29.
Article em En | MEDLINE | ID: mdl-38031096
BACKGROUND: The results of clinical trials should be completely and rapidly reported during public health emergencies such as COVID-19. This study aimed to examine when, and where, the results of COVID-19 clinical trials were disseminated throughout the first 18 months of the pandemic. METHODS: Clinical trials for COVID-19 treatment or prevention were identified from the WHO ICTRP database. All interventional trials with a registered completion date ≤ 30 June 2021 were included. Trial results, published as preprints, journal articles, or registry results, were located using automated and manual techniques across PubMed, Google Scholar, Google, EuropePMC, CORD-19, the Cochrane COVID-19 Study Register, and clinical trial registries. Our main analysis reports the rate of dissemination overall and per route, and the time from registered completion to results using Kaplan-Meier methods, with additional subgroup and sensitivity analyses reported. RESULTS: Overall, 1643 trials with completion dates ranging from 46 to 561 days prior to the start of results searches were included. The cumulative probability of reporting was 12.5% at 3 months from completion, 21.6% at 6 months, and 32.8% at 12 months. Trial results were most commonly disseminated in journals (n = 278 trials, 69.2%); preprints were available for 194 trials (48.3%), 86 (44.3%) of which converted to a full journal article. Trials completed earlier in the pandemic were reported more rapidly than those later in the pandemic, and those involving ivermectin were more rapidly reported than other common interventions. Results were robust to various sensitivity analyses except when considering only trials in a "completed" status on the registry, which substantially increased reporting rates. Poor trial registry data on completion status and dates limits the precision of estimates. CONCLUSIONS: COVID-19 trials saw marginal increases in reporting rates compared to standard practice; most registered trials failed to meet even the 12-month non-pandemic standard. Preprints were common, complementing journal publication; however, registries were underutilized for rapid reporting. Maintaining registry data enables accurate representation of clinical research; failing to do so undermines these registries' use for public accountability and analysis. Addressing rapid reporting and registry data quality must be emphasized at global, national, and institutional levels.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 4_TD Base de dados: MEDLINE Assunto principal: COVID-19 Limite: Humans Idioma: En Revista: BMC Med Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 4_TD Base de dados: MEDLINE Assunto principal: COVID-19 Limite: Humans Idioma: En Revista: BMC Med Ano de publicação: 2023 Tipo de documento: Article